Theremia funding news – Paris-based Theremia Raises €3 Million in Seed Funding

Funding Utilisation

The company will use the funds to grow its scientific team and build partnerships with medical institutes. Their goal is to improve their treatment personalization algorithm and expand their platform across Europe.

Aim of the Company

Theremia’s AI-powered platform aims to solve the problems with standard treatments that are often designed for a general patient type. It adjusts treatments to fit each patient's unique characteristics.

Read also - Oriole Networks funding news – London-based Oriole Networks Secures an Additional €20.2 Million Funding

It adjusts treatment factors like dosage, frequency, and drug type to make treatments more effective and reduce side effects, helping patients stick to their treatment plans. The company notes that around 60% of patients stop treatment because of side effects or lack of results.

It works closely with doctors, especially in neurology and psychiatry, to continually improve its algorithms and make sure they are accurate for different health conditions.

For drug developers, Theremia’s platform helps collect real-world data, showing how treatments work for specific patient groups—a key need in today’s healthcare system.

Theremia is led by Iris Maréchal, a former public health consultant, and Chloé Geoffroy, a pharmacist and neuroscience doctor. Their team includes experts from various fields of science and technology, all working to improve precision medicine.

About Theremia

Theremia is a health tech company focused on changing drug development with advanced AI. They specialize in creating better drug treatments for specific patient groups especially those with neurological disorders. The goal is to make treatments more effective reduce side effects and provide more personalized healthcare.